Company news

TheraCryf PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Investor Symposium

September 18, 2018

Notice of Investor Symposium

September 11, 2018

Final Patient Recruited in STEM Phase IIa Trial

July 25, 2018

Grant of share options, issue of equity and TVR

July 10, 2018

Evgen Pharma (EVG): 2018, a pivotal year

June 29, 2018

Evgen Pharma (EVG): Encouraging interim data fr...

June 13, 2018

Interim Update on STEM Trial

June 11, 2018

Upcoming Investor Presentations

May 14, 2018

Presentation at World Orphan Drug Congress USA

April 24, 2018

Research Collaboration with Imperial College

March 20, 2018

Update on Novel Sulforaphane Analogues

March 5, 2018

Poster Presentation of SFX-01 Mechanistic Data

January 15, 2018

Notification of Major Interest in Shares

January 10, 2018

Total Voting Rights

January 2, 2018

Collaboration with King's College London

December 13, 2017

Hardman Res.: Funded to the end of Phase II trials

December 11, 2017

First European Patent Grant

October 4, 2017

SFX-01 data published in Peer Reviewed Journal

August 2, 2017

Charity-funded Study of SFX-01 in TNBC

July 11, 2017

Hardman Research: Making clinical progress

June 21, 2017

Compassionate Use Programme and Trials Update

June 1, 2017

Notice of Preliminary Results

May 25, 2017

Further US Patent Grant

March 28, 2017

Issue of Equity, PDMR Shareholding and TVR

March 6, 2017

Patent Grant in the United States

February 14, 2017

Services Agreement with APTrans

February 13, 2017

First Patient Dosed in Breast Cancer Trial

January 17, 2017

Positive DSMB Review of SAS Trial

January 11, 2017

Half Yearly Report

December 5, 2016

Hardman Research: Clinical sulforaphane potential

November 29, 2016

Notice of Interim Results

November 17, 2016

Update re SFX-01 Data at ECTRIMS 2016

September 15, 2016

Presentation of SFX-01 Data at ECTRIMS 2016

September 8, 2016

Orphan Designation in the USA in SAH

August 24, 2016

Approval for Phase II Study in Breast Cancer

August 17, 2016

First Patient Dosed in Phase II Trial

May 3, 2016

Approval of Phase II Clinical Trial in SAH

March 2, 2016

Correction: Director Share Purchases

January 19, 2016

Exercise of Options

January 11, 2016

Appoints Chief Medical Officer

January 4, 2016

Expands Pipeline with Novel Compounds

November 23, 2015

First Day of Dealings

October 21, 2015

Offer Update - Office of Fair Trading Approval

November 25, 2011

Interim Management Statement

November 18, 2011

Offer Update

November 8, 2011

Results of Court Meeting and General Meeting

October 27, 2011

Private Client Acquisition

October 20, 2011

Amendment to the Scheme Document

October 4, 2011

Posting of Scheme Document

October 3, 2011

Statement re Offer Approaches

September 12, 2011

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.